Nano vs Resistant Tuberculosis: Taking the Lung Route.

Area of Science:

• Medical Microbiology
• Nanotechnology
• Pharmacology

Background:

• Tuberculosis (TB) remains a leading global infectious killer, with millions of deaths annually.
• Treatment non-adherence fuels the rise of multi-drug resistant (MDR) and extensively drug-resistant (XDR) TB.
• Conventional treatments struggle to eliminate TB reservoirs in alveoli and face drug resistance challenges.

Purpose of the Study:

• To review the significance and recent advancements in pulmonary drug delivery systems utilizing nanotechnology for TB treatment.
• To explore the potential of nanotechnology in overcoming TB drug resistance and improving patient compliance.
• To discuss the prevalence of TB, the necessity for nanomedicine development, nanocarrier benefits, safety, and clinical applications.

Main Methods:

• Literature review focusing on nanotechnology applications in pulmonary drug delivery for TB.
• Analysis of research on nanocarriers for targeting TB reservoirs in the lungs.
• Examination of studies on combating MDR and XDR-TB using nanomedicine strategies.

Main Results:

• Nanotechnology presents a viable strategy for accurate diagnosis and effective treatment of TB, including MDR and XDR strains.
• Pulmonary drug delivery via nanotechnology can enhance treatment efficacy against lung TB reservoirs.
• Nanomedicine offers potential for improved patient compliance and overcoming recurrent TB infections.

Conclusions:

• Nanotechnology holds significant promise for developing advanced pulmonary drug delivery systems to combat the growing threat of drug-resistant TB.
• Targeted delivery to the lungs via nanocarriers can improve therapeutic outcomes and address limitations of current TB treatments.
• Further research and clinical studies are crucial to fully realize the potential of nanomedicine in TB management.